2, 4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors
Compounds of general formula (I) are provided that are useful in the treatment of ATR kinase mediated diseases, such as proliferative diseases, such as cancer. Also provided are pharmaceutical compositions of the compounds of general formula (I), their use for the treatment of ATR kinase mediated di...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ZHANG HONGLEI LIU YANAN LI JINGTAO ZHOU LIYING MAO LI LI JING ZHONG WEITING LIU WEINA LIU BIN WANG HONGJUN XU HUIFEN ZHAO JING HUANG CHUANGCHUANG ZHAO YANPING JIANG YUANYUAN TIAN NANA |
| description | Compounds of general formula (I) are provided that are useful in the treatment of ATR kinase mediated diseases, such as proliferative diseases, such as cancer. Also provided are pharmaceutical compositions of the compounds of general formula (I), their use for the treatment of ATR kinase mediated diseases, and their preparation.
提供通式(I)化合物，它们可用于治疗ATR激酶介导的疾病，例如增生性疾病，例如癌症。还提供通式(I)化合物的药物组合物、其用于治疗ATR激酶介导的疾病的用途、及其制备。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN115551860A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN115551860A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN115551860A3</originalsourceid><addsrcrecordid>eNrjZHAx0lEw0VEw0y0pyiwuTSouySwpLUlNUSioLMrMzUzJzEtVSM7PLcgvzUspVkgsVnAMCVLIzsxLLE5VyMzLyEzKLMkvKuZhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGpqamhhZmBo7GxKgBACF1Md4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>2, 4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors</title><source>esp@cenet</source><creator>ZHANG HONGLEI ; LIU YANAN ; LI JINGTAO ; ZHOU LIYING ; MAO LI ; LI JING ; ZHONG WEITING ; LIU WEINA ; LIU BIN ; WANG HONGJUN ; XU HUIFEN ; ZHAO JING ; HUANG CHUANGCHUANG ; ZHAO YANPING ; JIANG YUANYUAN ; TIAN NANA</creator><creatorcontrib>ZHANG HONGLEI ; LIU YANAN ; LI JINGTAO ; ZHOU LIYING ; MAO LI ; LI JING ; ZHONG WEITING ; LIU WEINA ; LIU BIN ; WANG HONGJUN ; XU HUIFEN ; ZHAO JING ; HUANG CHUANGCHUANG ; ZHAO YANPING ; JIANG YUANYUAN ; TIAN NANA</creatorcontrib><description>Compounds of general formula (I) are provided that are useful in the treatment of ATR kinase mediated diseases, such as proliferative diseases, such as cancer. Also provided are pharmaceutical compositions of the compounds of general formula (I), their use for the treatment of ATR kinase mediated diseases, and their preparation.
提供通式(I)化合物，它们可用于治疗ATR激酶介导的疾病，例如增生性疾病，例如癌症。还提供通式(I)化合物的药物组合物、其用于治疗ATR激酶介导的疾病的用途、及其制备。</description><language>chi ; eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221230&DB=EPODOC&CC=CN&NR=115551860A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221230&DB=EPODOC&CC=CN&NR=115551860A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHANG HONGLEI</creatorcontrib><creatorcontrib>LIU YANAN</creatorcontrib><creatorcontrib>LI JINGTAO</creatorcontrib><creatorcontrib>ZHOU LIYING</creatorcontrib><creatorcontrib>MAO LI</creatorcontrib><creatorcontrib>LI JING</creatorcontrib><creatorcontrib>ZHONG WEITING</creatorcontrib><creatorcontrib>LIU WEINA</creatorcontrib><creatorcontrib>LIU BIN</creatorcontrib><creatorcontrib>WANG HONGJUN</creatorcontrib><creatorcontrib>XU HUIFEN</creatorcontrib><creatorcontrib>ZHAO JING</creatorcontrib><creatorcontrib>HUANG CHUANGCHUANG</creatorcontrib><creatorcontrib>ZHAO YANPING</creatorcontrib><creatorcontrib>JIANG YUANYUAN</creatorcontrib><creatorcontrib>TIAN NANA</creatorcontrib><title>2, 4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors</title><description>Compounds of general formula (I) are provided that are useful in the treatment of ATR kinase mediated diseases, such as proliferative diseases, such as cancer. Also provided are pharmaceutical compositions of the compounds of general formula (I), their use for the treatment of ATR kinase mediated diseases, and their preparation.
提供通式(I)化合物，它们可用于治疗ATR激酶介导的疾病，例如增生性疾病，例如癌症。还提供通式(I)化合物的药物组合物、其用于治疗ATR激酶介导的疾病的用途、及其制备。</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHAx0lEw0VEw0y0pyiwuTSouySwpLUlNUSioLMrMzUzJzEtVSM7PLcgvzUspVkgsVnAMCVLIzsxLLE5VyMzLyEzKLMkvKuZhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGpqamhhZmBo7GxKgBACF1Md4</recordid><startdate>20221230</startdate><enddate>20221230</enddate><creator>ZHANG HONGLEI</creator><creator>LIU YANAN</creator><creator>LI JINGTAO</creator><creator>ZHOU LIYING</creator><creator>MAO LI</creator><creator>LI JING</creator><creator>ZHONG WEITING</creator><creator>LIU WEINA</creator><creator>LIU BIN</creator><creator>WANG HONGJUN</creator><creator>XU HUIFEN</creator><creator>ZHAO JING</creator><creator>HUANG CHUANGCHUANG</creator><creator>ZHAO YANPING</creator><creator>JIANG YUANYUAN</creator><creator>TIAN NANA</creator><scope>EVB</scope></search><sort><creationdate>20221230</creationdate><title>2, 4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors</title><author>ZHANG HONGLEI ; LIU YANAN ; LI JINGTAO ; ZHOU LIYING ; MAO LI ; LI JING ; ZHONG WEITING ; LIU WEINA ; LIU BIN ; WANG HONGJUN ; XU HUIFEN ; ZHAO JING ; HUANG CHUANGCHUANG ; ZHAO YANPING ; JIANG YUANYUAN ; TIAN NANA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN115551860A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHANG HONGLEI</creatorcontrib><creatorcontrib>LIU YANAN</creatorcontrib><creatorcontrib>LI JINGTAO</creatorcontrib><creatorcontrib>ZHOU LIYING</creatorcontrib><creatorcontrib>MAO LI</creatorcontrib><creatorcontrib>LI JING</creatorcontrib><creatorcontrib>ZHONG WEITING</creatorcontrib><creatorcontrib>LIU WEINA</creatorcontrib><creatorcontrib>LIU BIN</creatorcontrib><creatorcontrib>WANG HONGJUN</creatorcontrib><creatorcontrib>XU HUIFEN</creatorcontrib><creatorcontrib>ZHAO JING</creatorcontrib><creatorcontrib>HUANG CHUANGCHUANG</creatorcontrib><creatorcontrib>ZHAO YANPING</creatorcontrib><creatorcontrib>JIANG YUANYUAN</creatorcontrib><creatorcontrib>TIAN NANA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHANG HONGLEI</au><au>LIU YANAN</au><au>LI JINGTAO</au><au>ZHOU LIYING</au><au>MAO LI</au><au>LI JING</au><au>ZHONG WEITING</au><au>LIU WEINA</au><au>LIU BIN</au><au>WANG HONGJUN</au><au>XU HUIFEN</au><au>ZHAO JING</au><au>HUANG CHUANGCHUANG</au><au>ZHAO YANPING</au><au>JIANG YUANYUAN</au><au>TIAN NANA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>2, 4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors</title><date>2022-12-30</date><risdate>2022</risdate><abstract>Compounds of general formula (I) are provided that are useful in the treatment of ATR kinase mediated diseases, such as proliferative diseases, such as cancer. Also provided are pharmaceutical compositions of the compounds of general formula (I), their use for the treatment of ATR kinase mediated diseases, and their preparation.
提供通式(I)化合物，它们可用于治疗ATR激酶介导的疾病，例如增生性疾病，例如癌症。还提供通式(I)化合物的药物组合物、其用于治疗ATR激酶介导的疾病的用途、及其制备。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN115551860A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | 2, 4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A45%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHANG%20HONGLEI&rft.date=2022-12-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN115551860A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |